A Phase I, Open-label, Multi-center, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of HMPL-453 in Patients With Advanced Solid Malignancies
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 14
- 试验地点
- 4
- 主要终点
- Incidence of DLTs by the NCI CTCAE v4.03
研究概览
简要总结
This is a first-time-in-human, phase I, open-label, dose-escalation study of HMPL-453 in patients with advanced or metastatic solid malignancies who have failed or are intolerable to standard therapies or for whom no standard therapies exist. There are preliminary two stages in this study: a dose-escalation stage (stage 1) and a dose-expansion stage (stage 2). We will decide whether to conduct stage 2 or not one month after the last patient included in stage 1.
详细描述
Dose-escalation stage (stage 1): Patients participating in the dose-escalation stage will take a single dose of HMPL-453 on Day 1 and will be followed for one week for safety observations. After one week of observation, if no safety issues occur, patients can continue multiple dosing of HMPL-453 QD and start on the DLT assessment cycles. Each cycle consists of 28-days. Patients are required to draw blood samples for PK and safety analysis at specific time points during the treatment.
The 3+3 design will be employed for the dose escalation and MTD determination. To limit the number of patients being exposed to potentially ineffective doses, one patient will be enrolled and dosed in the initial dose cohort. If there are no DLT or < 2 CTCAE grade 2 toxicities occur in the first treatment cycle, then the study will be escalated to the next dose cohort. Otherwise, the trial will revert to a standard 3+3 design.
Dose-Expansion Stage (Stage 2): This stage is to further evaluate the safety, tolerability, PD profile, and preliminary anti-tumor activity of HMPL-453 at the RP2D in approximately 10 patients with advanced solid tumor. Patients with FGFR dysregulated advanced solid tumors, including but not limited to, advanced gastric cancer, advanced urothelial bladder cancer, or advanced cholangiocarcinoma (patients with cancers of the gallbladder or ampulla of Vater are not eligible) are preferred to be enrolled.
Expansion stage will begin after dose-escalation stage is completed and the MTD/RP2D has been determined. Patients will receive HMPL-453 with 28-day treatment cycles until disease progression, death, intolerable toxicity, no longer benefiting from the study treatment per investigator's discretion, or withdrawal of consent, whichever comes first.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 25 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •In the dose escalation stage, patients with locally advanced, or metastatic solid tumor who have failed, or intolerable to, standard therapies or for whom no standard therapies exist will be enrolled.
- •In the dose expansion stage, patients with locally advanced, or metastatic solid tumor and FGFR dysregulation who have failed or intolerable to standard therapies or no standard therapies exist are to be enrolled.
- •In the dose escalation stage: evaluable or measurable disease according to RECIST Version 1.
- •In the dose expansion stage: measurable disease according to RECIST Version 1.
- •Life expectancy of at least 12 weeks.
- •ECOG performance status of 0 or 1
排除标准
- •Prior or current treatment with any selective FGFR inhibitor.
研究组 & 干预措施
HMPL-453
Two strengths of HMPL-453 tablets (25 mg and 100 mg based on the free base) will be used for clinical studies. The drug products are coated tablets, which are packaged in white induction sealed HDPE bottles. HMPL-453 will be administered to patients as oral tablet(s) on a daily basis, untill disease progression, intolerable toxicity, or death. Dose levels are to be potentially tested in this study include 25, 50, 100, 200, 300, 400, and 500 mg/day.
干预措施: HMPL-453 (Drug)
结局指标
主要结局
Incidence of DLTs by the NCI CTCAE v4.03
时间窗: Cycle 1 (DLT assessment window, 28 days) of multiple dosing peroid
次要结局
- Incidence of AEs, clinically significant laboratory abnormalities, and electrocardiographic (ECG) changes and vital signs(from first dose to 30 days after last dose of study treatment)
- maximum plasma concentration (Cmax)(from first dose to day 56 of multiple dosing peroid)
- Objective response rate (ORR)(Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks))
- terminal half-life (t1/2)(from first dose to day 56 of multiple dosing peroid)
- Duration of response (DoR)(Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks))
- Disease Control Rate (DCR)(Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks))
- Change in tumor size(Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks))
- area under the concentration-time curve (AUC0-t)(from first dose to day 56 of multiple dosing peroid)
- Progression free survival (PFS)(Every 8 weeks while being treated with HMPL-453 (expected average of 16 weeks))
- time to reach maximum concentration (Tmax)(from first dose to day 56 of multiple dosing peroid)
- apparent clearance (CL/F)(from first dose to day 56 of multiple dosing peroid)
- Serum phosphate level increases(from first dose to Day 21 of the last treatment cycle)